Biblio Discovery — Demo Discovery Service

46 hasil untuk "Gary Cutter"

Menampilkan 1–20 · 0,68 detik · RSS

  1. Artikel Jurnal

    Clinical trials in multiple sclerosis: milestones

    Yinan Zhang; Amber Salter; Gary Cutter dkk.

    Therapeutic Advances in Neurological Disorders, Vol. 11 · 2018 · Inggris · DOAJ Scopus

    The achievements in multiple sclerosis (MS) therapeutics are founded on the outcomes of clinical trials that demonstrate quantifiable results in treating a disease with an unpredictable course. Much has changed since the early trials in MS from the mid-20th century that compared a potential…

  2. Artikel Jurnal

    Which symptoms contribute the most to patients’ perception of health in multiple sclerosis?

    Rivka Green; Gary Cutter; Michael Friendly dkk.

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 3 · 2017 · Inggris · DOAJ Scopus

    Background Multiple sclerosis is a polysymptomatic disease. Little is known about relative contributions of the different multiple sclerosis symptoms to self-perception of health. Objectives To investigate the relationship between symptom severity in 11 domains affected by multiple sclerosis and…

  3. Artikel Jurnal

    Handling rescue therapy in myasthenia gravis clinical trials: why it matters and why you should care

    Justin M. Leach; Inmaculada Aban; Gary Cutter dkk.

    Annals of Clinical and Translational Neurology, Vol. 12 No. 5 · 2025 · Inggris · DOAJ Scopus

    Abstract Myasthenia gravis (MG) clinical trials typically allow rescue therapy during follow‐up in the event of marked worsening of MG symptoms. Failure to appropriately address rescue therapy in defining treatment effects and planning statistical analyses may yield biased estimates, increase false…

  4. Artikel Jurnal

    Evolution of clinical trials in multiple sclerosis

    Yinan Zhang; Amber Salter; Erik Wallström dkk.

    Therapeutic Advances in Neurological Disorders, Vol. 12 · 2019 · Inggris · DOAJ Scopus

    Clinical trials have advanced the treatment of multiple sclerosis (MS) by demonstrating the safety and efficacy of disease-modifying therapies (DMTs). This review discusses major changes to MS clinical trials in the era of DMTs. As treatment options for MS continue to increase, patients in modern…

  5. Artikel Jurnal

    Perceptions of physical activity guidelines among wheelchair users with multiple sclerosis

    Stephanie L. Silveira; Brenda Jeng; Gary Cutter dkk.

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 8 · 2022 · Inggris · DOAJ Scopus

    Background Physical activity guidelines provide prescriptive resources for population-level promotion of behavior change to improve health outcomes. The National Multiple Sclerosis Society (NMSS) recently created and disseminated physical activity guidelines for persons with multiple sclerosis (MS)…

  6. Artikel Jurnal

    Assessing the feasibility, theoretical interest, and observed behaviors of adding genetic data to a patient-reported multiple sclerosis registry

    Kaarina Kowalec; Douglas Menendez; Gary Cutter dkk.

    Multiple Sclerosis Journal - Experimental, Translational and Clinical, Vol. 12 · 2026 · Inggris · DOAJ Scopus

    Background and Objectives We aimed to assess the feasibility and acceptability of self-collected saliva for genetics from participants of a registry and determine whether responses to hypothetical questions regarding sharing of genetic information reflected observed behaviors. Methods We conducted…

  7. Artikel Jurnal

    Antibody responses to Chlamydia trachomatis vaccine candidate antigens in Chlamydia-infected women and correlation with antibody-mediated phagocytosis of elementary bodies

    Hong Yu; William M. Geisler; Chuanbin Dai dkk.

    Frontiers in Cellular and Infection Microbiology, Vol. 14 · 2024 · Inggris · DOAJ Scopus

    Murine research has revealed a significant role for antibody responses in protection against Chlamydia reinfection. To explore potential humoral immune markers of protection elicited by Chlamydia trachomatis (CT) antigens in humans in the context of presumed clinical correlates of protection, we…

  8. Artikel Jurnal

    Study protocol: exercise training for treating major depressive disorder in multiple sclerosis

    Robert W. Motl; Charles H. Bombardier; Jennifer Duffecy dkk.

    BMC Neurology, Vol. 24 No. 1 · 2024 · Inggris · DOAJ Scopus

    Abstract Background Major depressive disorder (MDD) is prevalent, yet sub-optimally treated among persons with multiple sclerosis (MS). We propose that exercise training may be a promising approach for treating depression in persons with MS who have MDD. Our primary hypothesis predicts a reduction…

  9. Artikel Jurnal

    The Effect of Body Mass Index on Brain Volume and Cognitive Function in Relapsing–Remitting Multiple sclerosis: A CombiRx Secondary Analysis

    Aliza Bitton Ben-Zacharia; Malvin N. Janal; Abraham A. Brody dkk.

    Journal of Central Nervous System Disease, Vol. 13 · 2021 · Inggris · DOAJ Scopus

    Background Multiple sclerosis (MS) is an autoimmune disease leading to physical, emotional and cognitive disability. High body mass index (BMI) may impact cognitive function and brain volume in MS. Yet, there is paucity of evidence addressing the impact of BMI on cognitive function and brain volume…

  10. Artikel Jurnal

    The association between BMI and cognition, disability, and quality of life markers in multiple sclerosis: DISCOMS secondary analysis

    Aliza Bitton Ben-Zacharia; Gary Cutter; Alya Shor dkk.

    Therapeutic Advances in Neurological Disorders, Vol. 19 · 2026 · Inggris · DOAJ Scopus

    Background: The association between body mass index (BMI) and cognition, disability, and quality of life (QoL) is controversial in multiple sclerosis (MS). Objectives: We investigated the association between BMI and cognitive function, disability, and QoL in MS. Methods: A cross-sectional secondary…

  11. Artikel Jurnal

    A propensity-matched comparison of long-term disability worsening in patients with multiple sclerosis treated with dimethyl fumarate or fingolimod

    Amber Salter; Samantha Lancia; Gary Cutter dkk.

    Therapeutic Advances in Neurological Disorders, Vol. 14 · 2021 · Inggris · DOAJ Scopus

    Background: Although the aggregate of data among patients with multiple sclerosis (MS) have shown similar efficacy between dimethyl fumarate (DMF) and fingolimod (FTY), most studies have not assessed long-term worsening of disability. We compared long-term disability worsening over 5 years, as…

  12. Artikel Jurnal

    Handling related publications reporting real-world evidence in network meta-analysis: a case study in multiple sclerosis

    Marissa Betts; Kyle Fahrbach; Binod Neupane dkk.

    Journal of Comparative Effectiveness Research (2023) · 2023 · Inggris · DOAJ Scopus

    Aim: The presence of two or more publications that report on overlapping patient cohorts poses a challenge for quantitatively synthesizing real-world evidence (RWE) studies. Thus, we evaluated eight approaches for handling such related publications in network meta-analyses (NMA) of RWE studies…

  13. Artikel Jurnal

    Low mortality rate in a large cohort of myelin oligodendrocyte glycoprotein antibody disease (MOGAD)

    Itay Lotan; Gabriela Romanow; Rebecca Salky dkk.

    Annals of Clinical and Translational Neurology, Vol. 10 No. 4 · 2023 · Inggris · DOAJ Scopus

    Abstract The mortality rates of individuals with myelin oligodendrocyte glycoprotein antibody disease (MOGAD) are currently unknown. This study aimed to assess the mortality rate in a large cohort of patients with MOGAD. Since none of the patients in our cohort died, we estimated the upper limit of…

  14. Artikel Jurnal Teks lengkap

    Causes of Death among Commercially Insured Multiple Sclerosis Patients in the United States

    Douglas S. Goodin; Michael Corwin; David Kaufman dkk.

    PLoS ONE, Vol. 9 No. 8 · 2014 · Inggris · PLOS Scopus

    Background: Information on causes of death (CODs) for patients with multiple sclerosis (MS) in the United States is sparse and limited by standard categorizations of underlying and immediate CODs on death certificates. Prior research indicated that excess mortality among MS patients was largely due…

    Juga tersedia di: DOAJ

  15. Artikel Jurnal Teks lengkap

    Outcomes and Risk Factors Associated With SARS-CoV-2 Infection in a North American Registry of Patients With Multiple Sclerosis

    Amber R. Salter; Robert J. Fox; Scott Douglas Newsome dkk.

    JAMA Neurology · 2021 · Inggris · OpenAlex Scopus

    Importance: Emergence of SARS-CoV-2 causing COVID-19 prompted the need to gather information on clinical outcomes and risk factors associated with morbidity and mortality in patients with multiple sclerosis (MS) and concomitant SARS-CoV-2 infections. Objective: To examine outcomes and risk factors…

  16. Artikel Jurnal

    Clinical risk factors for admission with Pseudomonas and multidrug-resistant Pseudomonas community-acquired pneumonia

    Adeniyi J. Idigo; J. Michael Wells; Matthew L. Brown dkk.

    Antimicrobial Resistance and Infection Control, Vol. 11 No. 1 · 2022 · Inggris · DOAJ Scopus

    Abstract Background Microbial etiology for community-acquired pneumonia (CAP) is evolving with pathogens known for high CAP mortality e.g., Pseudomonas species. Chronic obstructive pulmonary disease (COPD) patients are at risk for hospitalization for CAP. Understanding regional patterns and risk…

  17. Artikel Jurnal

    Visual spatial learning outcomes for clinical trials in neurofibromatosis type 1

    Nicole J. Ullrich; Jonathan M. Payne; Karin S. Walsh dkk.

    Annals of Clinical and Translational Neurology, Vol. 7 No. 2 · 2020 · Inggris · DOAJ Scopus

    Abstract Cognitive problems are common in children with neurofibromatosis type 1, representing a significant source of lifelong morbidity. Assessment of cognitive function has been challenging in the setting of clinical trials. Spatial learning deficits may be an important target for cognitive…

  18. Artikel Jurnal

    Clinical trials in multiple sclerosis: potential future trial designs

    Navid Manouchehri; Yinan Zhang; Amber Salter dkk.

    Therapeutic Advances in Neurological Disorders, Vol. 12 · 2019 · Inggris · DOAJ Scopus

    Clinical trials of new treatments in multiple sclerosis (MS) currently require large sample sizes and long durations in order to yield reliable results. The differential responses of an already heterogeneous population of MS patients to individual disease-modifying therapies (DMTs) will further…

  19. Artikel Jurnal

    Aging and efficacy of disease-modifying therapies in multiple sclerosis: a meta-analysis of clinical trials

    Yinan Zhang; Natalia Gonzalez Caldito; Afsaneh Shirani dkk.

    Therapeutic Advances in Neurological Disorders, Vol. 13 · 2020 · Inggris · DOAJ Scopus

    Background: Disease-modifying therapies (DMTs) for multiple sclerosis (MS) are approved for the treatment of disease activity and are effective in reducing relapses and new magnetic resonance imaging (MRI) lesions. However, disease activity generally subsides with time, and age-dependent changes in…